



ASX ANNOUNCEMENT

Lumos Receives Research & Development Tax Rebate

MELBOURNE, Australia (23 June 2025) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has received a cash refund of A\$215,485 related to its Research and Development Tax Incentive for the FY2024 financial year ended 30 June 2024.

The cash refund is mainly associated with Lumos' ongoing research and development efforts focused on enhancing its proprietary benchtop and disposable reader technology platform. This platform supports the detection of a broader range of clinical biomarkers, improves the interpretation of point-of-care test results, and allows for smooth integration with electronic medical records. It has become a key part of Lumos' value proposition and has played a significant role in securing contracts with partners such as Hologic and the Burnet Diagnostics Initiative at the MacFarlane Burnet Institute for Medical Research and Public Health Ltd.

The Australian Government's Research and Development Tax Incentive Refund provides eligible companies with cash refunds for 43.5% of eligible expenditure on research and development activities.

Doug Ward, CEO and Managing Director of Lumos Diagnostics commented, “We are pleased to receive this R&D tax refund, which supports our ongoing investment in innovation and product development. The funding assists with the evolution of our proprietary reader platform - a core component of our diagnostics offering that continues to attract significant interest. We remain committed to advancing point-of-care technologies that deliver meaningful clinical outcomes.”

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia
HACK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000 Australia
info@lumosdiagnostics.com
+61 3 9087 1598